Although AFP is increased > 400 ng/ml (the value considered diagnostic for HCC) in only 20–25% of patients with HCC, either with beta-thalassemia [1, 33] or without [54, 55], it allows to identify patients at risk when baseline values are > 20 ng/ml, or if they increase over time [56]. This evidence concerns the gene AFP and hepatocellular carcinoma.